Investigating phenotypes of pulmonary COVID-19 recovery - a longitudinal observational prospective multicenter trial
- Medical University of Innsbruck, Austria
- Data Analytics As a Service Tirol, Austria
- The Karl Landsteiner Institute, Austria
- University Hospital Innsbruck, Austria
- St. Vinzenz Hospital, Austria
Abstract
Background: The optimal procedures to prevent, identify, monitor and treat long-term pulmonary sequelae of COVID-19 are elusive. Here, we characterized the kinetics of respiratory and symptom recovery following COVID-19.
Methods: We conducted a longitudinal, multi-center observational study in ambulatory and hospitalized COVID-19 patients recruited in early 2020 (n = 145). Pulmonary computed tomography (CT) and lung function (LF) readouts, symptom prevalence, clinical and laboratory parameters were collected during acute COVID-19 and at 60-, 100- and 180-days follow-up visits. Recovery kinetics and risk factors were investigated by logistic regression. Classification of clinical features and participants was accomplished by unsupervised and semi-supervised multi-parameter clustering and machine learning.
Results: At the six-month follow-up, 49% of participants reported persistent symptoms. The frequency of structural lung CT abnormalities ranged from 18% in the mild outpatient cases to 76% in the ICU convalescents. Prevalence of impaired LF ranged from 14% in the mild outpatient cases to 50% in the ICU survivors. Incomplete radiological lung recovery was associated with increased anti-S1/S2 antibody titer, IL-6 and CRP levels at the early follow-up. We demonstrated that the risk of perturbed pulmonary recovery could be robustly estimated at early follow-up by clustering and machine learning classifiers employing solely non-CT and non-LF parameters.
Conclusion: The severity of acute COVID-19 and protracted systemic inflammation is strongly linked to persistent structural and functional lung abnormality. Automated screening of multi-parameter health record data may assist at the prediction of incomplete pulmonary recovery and optimize COVID-19 follow-up management.
Funding: The State of Tyrol (GZ 71934), Boehringer Ingelheim/Investigator initiated study (IIS 1199-0424).
Trial Registration: ClinicalTrials.gov: NCT04416100
Data availability
The complete R analysis pipeline and the anonymized study data in form of stratified study variables are available as a public GitHub repository: https://github.com/PiotrTymoszuk/CovILD_6_Months. The R code for the key tools used for uni-variate modeling and model quality control (Figures 4 and 5, https://github.com/PiotrTymoszuk/lm_qc_tools) as well as cluster analysis and its quality control (Figures 6 - 7, https://github.com/PiotrTymoszuk/clustering-tools-2) is available at GitHub.
Article and author information
Author details
Judith Löffler-Ragg
Funding
Landes Tirols (GZ 71934)
- Judith Löffler-Ragg
Boehringer Ingelheim (IIS 1199-0424)
- Ivan Tancevski
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Human subjects: All participants gave written informed consent. The study was approved by the institutional review board at the Medical University of Innsbruck (approval number: 1103/2020), and registered at ClinicalTrials.gov (NCT04416100).
Copyright
© 2022, Sonnweber et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,736
- views
-
- 288
- downloads
-
- 35
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Investigating phenotypes of pulmonary COVID-19 recovery - a longitudinal observational prospective multicenter trial
eLife 11:e72500.
https://doi.org/10.7554/eLife.72500
Further reading
-
- Medicine
- Microbiology and Infectious Disease
- Epidemiology and Global Health
- Immunology and Inflammation
eLife has published articles on a wide range of infectious diseases, including COVID-19, influenza, tuberculosis, HIV/AIDS, malaria and typhoid fever.
-
- Epidemiology and Global Health
Given the rapid cross-country spread of SARS-CoV-2 and the resulting difficulty in tracking lineage spread, we investigated the potential of combining mobile service data and fine-granular metadata (such as postal codes and genomic data) to advance integrated genomic surveillance of the pandemic in the federal state of Thuringia, Germany. We sequenced over 6500 SARS-CoV-2 Alpha genomes (B.1.1.7) across 7 months within Thuringia while collecting patients’ isolation dates and postal codes. Our dataset is complemented by over 66,000 publicly available German Alpha genomes and mobile service data for Thuringia. We identified the existence and spread of nine persistent mutation variants within the Alpha lineage, seven of which formed separate phylogenetic clusters with different spreading patterns in Thuringia. The remaining two are subclusters. Mobile service data can indicate these clusters’ spread and highlight a potential sampling bias, especially of low-prevalence variants. Thereby, mobile service data can be used either retrospectively to assess surveillance coverage and efficiency from already collected data or to actively guide part of a surveillance sampling process to districts where these variants are expected to emerge. The latter concept was successfully implemented as a proof-of-concept for a mobility-guided sampling strategy in response to the surveillance of Omicron sublineage BQ.1.1. The combination of mobile service data and SARS-CoV-2 surveillance by genome sequencing is a valuable tool for more targeted and responsive surveillance.
